产品
编 号：F251683
分子式：C14H19N5O5
分子量：337.33
分子式：C14H19N5O5
分子量：337.33
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 204512-90-3
产品详情
生物活性：
Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist.
体内研究：
In atrial-paced anaesthetized guinea-pigs, intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson given at 50 μg/kg causes a significant bradycardia (50% decrease in heart rate at 25 min.
体外研究：
In the atrial-paced isolated heart, Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that causes equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly reduces left ventricular developed pressure (LVP) and markedly increases coronary conductance. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP).
Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist.
体内研究：
In atrial-paced anaesthetized guinea-pigs, intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson given at 50 μg/kg causes a significant bradycardia (50% decrease in heart rate at 25 min.
体外研究：
In the atrial-paced isolated heart, Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that causes equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly reduces left ventricular developed pressure (LVP) and markedly increases coronary conductance. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备